Humanized mouse models in drug discovery research

American Pharmaceutical Review

Volumn 15, Issue 4, 2012, Pages

  Qin, Wenning ^b   Stock, Jeffrey L ^b   Sacca, Rosalba ^a  

^a Scientific Development   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

MARAVIROC; THROMBOPOIETIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; BONE MARROW TRANSPLANTATION; CANCER CELL CULTURE; DISEASE MODEL; DNA MODIFICATION; DRUG DEVELOPMENT; GENE THERAPY; HUMAN; HUMAN GENETICS; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IN VIVO STUDY; MEDICAL RESEARCH; METASTASIS; NONHUMAN; ONCOLOGY; PROMYELOCYTIC LEUKEMIA; REVIEW; SWINE; THROMBOCYTOPENIA; TRANSGENIC ANIMAL; TUMOR GROWTH; XENOGRAFT;

EID: 84864149297     PISSN: 10998012     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. Zambrowicz, B.P. and Sands, A.T. (2003) Knockouts model the 100 best-selling drugs - will they model the next 100? Nat Rev Drug Discov 2 (1), 38-51 (Pubitemid 37361623)
2. Shultz, L.D. et al. (2007) Humanized mice in translational biomedical research. Nat Rev Immunol 7 (2), 118-130 (Pubitemid 46174859)
3. Melkus, M.W. et al. (2006) Humanized mice mount specific adaptive and innate immune responses to EBV and TSST-1. Nat Med 12 (11), 1316-1322 (Pubitemid 44706935)
4. Kola, I. and Landis, J. (2004) Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 3 (8), 711-715 (Pubitemid 39173511)
5. Kakizuka, A. et al. (1991) Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML. Cell 66 (4), 663-674 (Pubitemid 121001702)
6. Grisolano, J.L. et al. (1997) Altered myeloid development and acute leukemia in transgenic mice expressing PML-RAR alpha under control of cathepsin G regulatory sequences. Blood 89 (2), 376-387 (Pubitemid 27051671)
7. He, L.Z. et al. (1997) Acute leukemia with promyelocytic features in PML/RARalpha transgenic mice. Proc Natl Acad Sci U S A 94 (10), 5302-5307
8. Brown, D. et al. (1997) A PMLRARalpha transgene initiates murine acute promyelocytic leukemia. Proc Natl Acad Sci U S A 94 (6), 2551-2556 (Pubitemid 27136913)
9. Rego, E.M. et al. (2000) Retinoic acid (RA) and As2O3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARalpha and PLZF-RARalpha oncoproteins. Proc Natl Acad Sci U S A 97 (18), 10173-10178
10. He, L.Z. et al. (2001) Histone deacetylase inhibitors induce remission in transgenic models of therapyresistant acute promyelocytic leukemia. J Clin Invest 108 (9), 1321-1330
11. Waterston, R.H. et al. (2002) Initial sequencing and comparative analysis of the mouse genome. Nature 420 (6915), 520-562 (Pubitemid 35477048)
12. Wartman, L.D. et al. (2011) Sequencing a mouse acute promyelocytic leukemia genome reveals genetic events relevant for disease progression. J Clin Invest 121 (4), 1445-1455
13. Vigon, I. et al. (1992) Molecular cloning and characterization of MPL, the human homolog of the v-mpl oncogene: identification of a member of the hematopoietic growth factor receptor superfamily. Proc Natl Acad Sci U S A 89 (12), 5640-5644
14. Mignotte, V. et al. (1994) Structure and transcription of the human c-mpl gene (MPL). Genomics 20 (1), 5-12 (Pubitemid 24100913)
15. Erickson-Miller, C.L. et al. (2005) Discovery and characterization of a selective, nonpeptidyl thrombopoietin receptor agonist. Exp Hematol 33 (1), 85-93 (Pubitemid 40127647)
16. Nakamura, T. et al. (2006) A novel nonpeptidyl human c-Mpl activator stimulates human megakaryopoiesis and thrombopoiesis. Blood 107 (11), 4300-4307 (Pubitemid 43801354)
17. Reiter, L.A. et al. (2007) Pyrimidine benzamide-based thrombopoietin receptor agonists. Bioorg Med Chem Lett 17 (19), 5447-5454 (Pubitemid 47391272)
18. Yamane, N. et al. (2008) Characterization of novel non-peptide thrombopoietin mimetics, their species specificity and the activation mechanism of the thrombopoietin receptor. Eur J Pharmacol 586 (1-3), 44-51
19. Erickson-Miller, C.L. et al. (2009) Preclinical activity of eltrombopag (SB-497115), an oral, nonpeptide thrombopoietin receptor agonist. Stem Cells 27 (2), 424-430
20. Nogami, W. et al. (2008) The effect of a novel, small non-peptidyl molecule butyzamide on human thrombopoietin receptor and megakaryopoiesis. Haematologica 93 (10), 1495-1504
21. Antipas, A.S. et al. (2010) Structure-activity relationships and hepatic safety risks of thiazole agonists of the thrombopoietin receptor. Bioorg Med Chem Lett 20 (14), 4069-4072
22. Liu, R. et al. (1996) Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 86 (3), 367-377 (Pubitemid 26272077)
23. Dorr, P. et al. (2005) Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother 49 (11), 4721-4732 (Pubitemid 41552605)
24. Kim, Y.G. et al. (1996) Hybrid restriction enzymes: zinc finger fusions to Fok I cleavage domain. Proc Natl Acad Sci U S A 93 (3), 1156-1160
25. Perez, E.E. et al. (2008) Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases. Nat Biotechnol 26 (7), 808-816 (Pubitemid 351961450)
26. Holt, N. et al. (2010) Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo. Nat Biotechnol 28 (8), 839-847
27. Rogers, C.S. et al. (2008) Disruption of the CFTR gene produces a model of cystic fibrosis in newborn pigs. Science 321 (5897), 1837-1841
28. Aitman, T.J. et al. (2008) Progress and prospects in rat genetics: a community view. Nat Genet 40 (5), 516-522 (Pubitemid 351601225)
29. Tong, C. et al. (2010) Production of p53 gene knockout rats by homologous recombination in embryonic stem cells. Nature 467 (7312), 211-213
30. Geurts, A.M. et al. (2009) Knockout rats via embryo microinjection of zinc-finger nucleases. Science 325 (5939), 433
31. Tesson, L. et al. (2011) Knockout rats generated by embryo microinjection of TALENs. Nat Biotechnol 29 (8), 695-696
32. Suntharalingam, G. et al. (2006) Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 355 (10), 1018-1028 (Pubitemid 44343545)
33. Eastwood, D. et al. (2010) Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4+ effector memory T-cells. Br J Pharmacol 161 (3), 512-526
34. Smithies, O. et al. (1985) Insertion of DNA sequences into the human chromosomal beta-globin locus by homologous recombination. Nature 317 (6034), 230-234 (Pubitemid 16246494)
35. Thomas, K.R. et al. (1986) High frequency targeting of genes to specific sites in the mammalian genome. Cell 44 (3), 419-428 (Pubitemid 16043333)
36. Kuehn, M.R. et al. (1987) A potential animal model for Lesch-Nyhan syndrome through introduction of HPRT mutations into mice. Nature 326 (6110), 295-298 (Pubitemid 17053753)
37. Brinster, R.L. and Palmiter, R.D. (1984) Transgenic mice containing growth hormone fusion genes. Philos Trans R Soc Lond B Biol Sci 307 (1132), 309-312
38. Traggiai, E. et al. (2004) Development of a human adaptive immune system in cord blood celltransplanted mice. Science 304 (5667), 104-107 (Pubitemid 38451466)
39. Shultz, L.D. et al. (2005) Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells. J Immunol 174 (10), 6477-6489 (Pubitemid 40663843)